Chapter Update Summary

8/18/2015

11/6/2014

1/10/2014

10/24/2013

7/18/2013

7/17/2012

10/25/2011

11/23/2010

  • Updated to include data showing higher levels of d-dimer and C-reactive protein among patients who develop IRIS during antiretroviral therapy; new prevalence data on IRIS in patients initiating antiretroviral therapy; studies evaluating timing of antiretroviral therapy in the setting of TB; a publication of ACTG A5164 data evaluating Cryptococcus as a presenting OI; and prevalence data for paradoxical IRIS in patients initiating antiretroviral therapy with Kaposi‚Äôs sarcoma.